Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison Study of Cord Blood and GPBSC on Microtransplantation for Treatment of Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04174586
Recruitment Status : Not yet recruiting
First Posted : November 22, 2019
Last Update Posted : November 22, 2019
Sponsor:
Information provided by (Responsible Party):
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Compare the effectiveness and safety of cord blood with HLA-mismatched donor cells infusion on microtransplantation for treatment of acute myeloid leukemia

Condition or disease Intervention/treatment Phase
Safety Issues Efficiency Biological: microtransplantation Phase 1

Detailed Description:
The investigators conducted a prospective, multicenter clinical trial of HLA-mismatched MST to to compare the outcomes and toxicities of cord blood with HLA-mismatched donor cells infusion after chemotherapy (microtransplantation) in older patients with acute myeloid leukemia (AML)

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison Study of Cord Blood and GPBSC on Microtransplantation for Treatment of Acute Myeloid Leukemia
Estimated Study Start Date : December 1, 2019
Estimated Primary Completion Date : August 31, 2024
Estimated Study Completion Date : August 31, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: cord blood group
standard induction and consolidation chemotherapy with cord blood microtransplantation
 Biological: microtransplantation
HLA mismatched donor cord blood infusion
No Intervention: G-CSF mobilized peripheral blood
standard induction and consolidation chemotherapy with G-CSF mobilized HLA -mismatched peripheral blood stem cells microtransplantation


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. complete remission rate [ Time Frame: 1 month ]
    Bone marrow <5% blasts； Absolute neutrophil count >1000/mcL； Platelets ≥100,000/mcL；No residual evidence of extramedullary disease.

  2. time of hematopoietic recovery [ Time Frame: 1 month ]
    Absolute neutrophil count >500/mcL; Platelets ≥20,000/mcL


Secondary Outcome Measures :
  1. time to progression [ Time Frame: 2 year ]
    Measured from complete remission to the relapse


Other Outcome Measures:
  1. diease free survival [ Time Frame: 2 year ]
    Measured from complete remission to the date of death or the date of last follow-up examination.

  2. overall survival [ Time Frame: 2 year ]
    Measured from the date of beginning therapy to the date of death or the date of last follow-up examination.

  3. rate of early mortality [ Time Frame: 1 month ]
    Death within 4 weeks after initiation of induction therapy


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. de novo acute myeloid leukemia
  2. age 60-80
  3. have HLA mismatched donor

Exclusion Criteria:

  1. have no suitable donor or donor refused
  2. patient refused to accept donor cells
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
ClinicalTrials.gov Identifier: NCT04174586     History of Changes
Other Study ID Numbers: CB-GPBSC 001
First Posted: November 22, 2019    Key Record Dates
Last Update Posted: November 22, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Affiliated Hospital of the Chinese Academy of Military Medical Sciences:
Cord blood microtransplatation
mobilized prepheral stem cell microtransplatation
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid, Acute
Leukemia
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid